The prices of Neomycin Sulphate are expected to remain elevated globally by the end of May 2024, continuing the trend observed in the prior month. This uptick is chiefly propelled by sustained robust demand from the healthcare and pharmaceutical sectors, coupled with constrained inventories in the market. In anticipation of this demand surge, market participants strategically raised Neomycin Sulphate prices, taking advantage of the current market conditions, contributing to a prevailing bullish sentiment.

In China, Neomycin Sulphate prices have recently remained on the elevated trajectory due to tighter supply from mainstream factories, resulting in increased domestic transaction prices. Furthermore, the National Bureau of Statistics (NBS) reports that China's manufacturing activity in May continued to grow at a similar rate to the previous month, indicating sustained expansion and forecasting continued industrial recovery into the second quarter. This ongoing growth in manufacturing activity indicates a consistent demand for various goods within the Chinese market, including Active Pharmaceutical Ingredients (APIs) like Neomycin Sulphate. Additionally, there has been a notable increase in new export orders, underscoring the resilience of Western economies and further fuelling the upward pricing trend for Neomycin Sulphate.

Meanwhile, the Eurozone has effectively emerged from an economic downturn, with its four largest economies experiencing stronger-than-anticipated growth. Recent economic indicators demonstrate that the Eurozone's efforts towards recovery are yielding positive results, marking a transition from the previous period of economic decline. With improved domestic economic conditions, consumers are displaying a greater propensity to spend, thereby driving up demand for commodities such as Neomycin Sulphate within the Eurozone. Similarly, in the USA, the economy is undergoing a gradual stabilization, in contrast to earlier predictions of a severe downturn. Despite concerns regarding costs, consumers are demonstrating resilience and a willingness to spend, as evidenced by robust retail sales figures, which further bolster the upward trajectory of Neomycin Sulphate.

As of the first quarter of 2024, the US experienced a decade-high shortage of 323 drugs across 22 therapeutic categories, marking a significant increase from the stable range of 300-310 drugs in 2023. This spike in shortages creates an urgent demand for various medications, including antibiotics like Neomycin Sulphate, presenting a lucrative opportunity for Indian pharmaceutical exporters. As they step in to fill the supply gap in the US market, the heightened demand and limited availability are likely to drive up the prices of essential drugs like Neomycin Sulphate. Consequently, Indian pharmaceutical companies can capitalize on this scenario by negotiating higher prices, thereby contributing to the overall increase in Neomycin Sulphate prices.

According to ChemAnalyst analysis, the prices of Neomycin Sulphate are projected to keep ascending in the coming months, propelled by sustained consumer demand amidst constrained market supply. Additionally, there are expectations that Western economies might opt to decrease key interest rates in June, a move that could amplify demand and maintain a positive market outlook.